These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 5443539)

  • 21. [Cytostatic alopecia, including thallium alopecia].
    Herzberg JJ
    Arch Klin Exp Dermatol; 1966; 227(1):452-68. PubMed ID: 5984790
    [No Abstract]   [Full Text] [Related]  

  • 22. Recurrent herpes labialis during isotretinoin therapy: is there a role for photosensitivity?
    Yazici AC; Baz K; Ikizoglu G
    J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):93-5. PubMed ID: 16405618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verweij J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S180-4. PubMed ID: 8453694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide in the treatment of malignant diseases.
    Kini PM; Sivakumar S; Pai KN
    J Indian Med Assoc; 1965 Aug; 45(4):195-200. PubMed ID: 5826083
    [No Abstract]   [Full Text] [Related]  

  • 25. [Apropos of the treatment of malignant tumors by continuous endolymphatic chemotherapy].
    Thépot J
    Mem Acad Chir (Paris); 1965 Jun 9-16; 91(19):607-16. PubMed ID: 4284307
    [No Abstract]   [Full Text] [Related]  

  • 26. [Massive cytostatic therapy after orthovoltage therapy].
    Schawow A
    Radiobiol Radiother (Berl); 1970; 11(6):655-9. PubMed ID: 5509232
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II evaluation of vindesine sulfate in patients with advanced sarcomas.
    Sordillo PP; Magill GB; Gralla RJ
    Cancer Treat Rep; 1981; 65(5-6):515-6. PubMed ID: 7237472
    [No Abstract]   [Full Text] [Related]  

  • 28. The course of nausea and vomiting after high-dose cyclophosphamide.
    Fetting JH; Grochow LB; Folstein MF; Ettinger DS; Colvin M
    Cancer Treat Rep; 1982 Jul; 66(7):1487-93. PubMed ID: 7093965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxicity and side effects of cyclophosphamide].
    García Dadoni L; Rafael Seoane M
    Rev Clin Esp; 1968 Apr; 109(1):11-6. PubMed ID: 5738821
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cyclophosphamide infusion (Druckrey's "shock-therapy") in the treatment of malignant lung tumors].
    Beumer HM
    Ned Tijdschr Geneeskd; 1965 Sep; 109(36):1648-52. PubMed ID: 5318275
    [No Abstract]   [Full Text] [Related]  

  • 31. [First clinical experiences with ultrahigh single doses of cyclophosphamide].
    Schmitz G; Gross R
    Med Welt; 1967 Apr; 16():985-9. PubMed ID: 5585096
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
    Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
    Terazaki Y; Nagamatsu H; Ono H; Iwakuma N; Shirouzu K
    Gan To Kagaku Ryoho; 2005 May; 32(5):675-7. PubMed ID: 15918571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous and other complications of cyclophosphamide: a brief review.
    Jessen RT; Straight M; Smith EB
    Rocky Mt Med J; 1978; 75(4):204-6. PubMed ID: 684340
    [No Abstract]   [Full Text] [Related]  

  • 35. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens.
    Janssen WE; Smilee R; Carter R; Rahn D; Cairo M; Hiemenz JH; Zorsky PE; Fields KK; Ballester O; Perkins J
    Prog Clin Biol Res; 1994; 389():429-39. PubMed ID: 7700915
    [No Abstract]   [Full Text] [Related]  

  • 36. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
    Rudolf Z; Plesnicar S
    Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further observations on two unusual complications of topical fluorouracil therapy.
    Burnett JW
    Arch Dermatol; 1982 Feb; 118(2):74. PubMed ID: 7059221
    [No Abstract]   [Full Text] [Related]  

  • 40. [Bladder cancer and malignant melanoma following Endoxan therapy of a lymphoproliferative disease].
    Kaufmann B; Wegmann W
    Schweiz Med Wochenschr; 1981 Apr; 111(15):540-5. PubMed ID: 7233132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.